Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 12, 2011, Pages 9108-9115

  Su, Wenru ^a   Li, Zhanrong ^a   Li, Yongping ^a   Lin, Miaoli ^a   Yao, Lin ^a   Liu, Yi ^a   He, Zixin ^b   Wu, Chuanbin ^b   Liang, Dan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXYCYCLINE; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; MMP2 PROTEIN, RAT; MONOCLONAL ANTIBODY; NOS2 PROTEIN, RAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUSTIC BURN; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA PERFORATION; CORNEA ULCER; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYDROGEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SKIN DEFECT; SLIT LAMP; WESTERN BLOTTING; WOUND HEALING; ANIMAL; CHEMICAL BURN; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; EYE BURN; METABOLISM; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOTTING, WESTERN; BURNS, CHEMICAL; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOXYCYCLINE; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE BURNS; FEMALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

EID: 84862833119     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7255     Document Type: Article

References (55)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Lim P, Fuchsluger TA, Jurkunas UV. Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol. 2009;24:139-148.
3. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
4. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
5. Chen WL, Lin CT, Lin NT, et al. Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci. 2009;50:1659-1665.
6. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127:381-389.
7. Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK. Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci. 2009;50:4653-4659.
8. Kim EC, Lee WS, Kim MS. The inhibitory effects of bevacizumab eye drops on NGF expression and corneal wound healing in rats. Invest Ophthalmol Vis Sci. 2010;51:4569-4573.
9. Jacobs DS, Lim M, Carrasquillo KG, Rosenthal P. Bevacizumab for corneal neovascularization. Ophthalmology. 2009;116:592-593; author reply 593-594.
10. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92:10457-10461.
11. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302.
12. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006;354:2621-2622.
13. Villarreal FJ, Griffin M, Omens J, et al. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation. 2003;108:1487-1492.
14. Lindeman JH, Abdul-Hussien H, van Bockel JH, et al. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation. 2009;119:2209-2216.
15. Saikali Z, Singh G. Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs. 2003;14:773-778.
16. Ralph RA. Tetracyclines and the treatment of corneal stromal ulceration: a review. Cornea. 2000;19:274-277.
17. Seedor JA, Perry HD, McNamara TF, et al. Systemic tetracycline treatment of alkali-induced corneal ulceration in rabbits. Arch Ophthalmol. 1987;105:268-271.
18. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci. 1989;30:1569-1575.
19. Cykiert RC. Systemic tetracycline therapy for epithelial defects. Ophthalmology. 1987;94:894-895.
20. Perry HD, Kenyon KR, Lamberts DW, et al. Systemic tetracycline hydrochloride as adjunctive therapy in the treatment of persistent epithelial defects. Ophthalmology. 1986;93:1320-1322.
21. Dursun D, Kim MC, Solomon A, Pflugfelder SC. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132:8-13.
22. Perry HD, Hodes LW, Seedor JA, et al. Effect of doxycycline hyclate on corneal epithelial wound healing in the rabbit alkali-burn model: preliminary observations. Cornea. 1993;12:379-382.
23. Samtani S, Amaral J, Campos MM, et al. Doxycycline-mediated inhibition of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2009;50:5098-5106.
24. Cox CA, Amaral J, Salloum R, et al. Doxycycline's effect on ocular angiogenesis: an in vivo analysis. Ophthalmology. 2010;117:1782-1791.
25. Dan L, Shi-long Y, Miao-li L, et al. Inhibitory effect of oral doxycycline on neovascularization in a rat corneal alkali burn model of angiogenesis. Curr Eye Res. 2008;33:653-660.
26. Su W, Li Z, Lin M, et al. The effect of doxycycline temperaturesensitive hydrogel on inhibiting the corneal neovascularization induced by bFGF in rats. Graefes Arch Clin Exp Ophthalmol. 2011;249:421-427.
27. Anumolu SS, DeSantis AS, Menjoge AR, et al. Doxycycline loaded poly(ethylene glycol) hydrogels for healing vesicant-induced ocular wounds. Biomaterials. 2010;31:964-974.
28. Kenyon BM, Voest EE, Chen CC, et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996;37:1625-1632.
29. Belotti D, Paganoni P, Manenti L, et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res. 2003;63:5224-5229.
30. Chetty C, Lakka SS, Bhoopathi P, Rao JS. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer. 2010;127:1081-1095.
31. Badiga AV, Chetty C, Kesanakurti D, et al. MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS ONE. 2011; 6:e20614.
32. Kawamura T, Murakami K, Bujo H, et al. Matrix metalloproteinase-3 enhances the free fatty acids-induced VEGF expression in adipocytes through toll-like receptor 2. Exp Biol Med. 2008;233: 1213-1221.
33. Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci. 2004;117:1847-1857.
34. Wilson SE, Mohan RR, Mohan RR, et al. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res. 2001;20:625-637.
35. Wilson SE, Esposito A. Focus on molecules: interleukin-1: a master regulator of the corneal response to injury. Exp Eye Res. 2009;89: 124-125.
36. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994;94:2036-2044.
37. Sagoo P, Chan G, Larkin DF, George AJ. Inflammatory cytokines induce apoptosis of corneal endothelium through nitric oxide. Invest Ophthalmol Vis Sci. 2004;45:3964-3973.
38. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419-428.
39. Sounni NE, Janssen M, Foidart JM, Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol. 2003;22:55-61.
40. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res. 1998;55:29-42.
41. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
42. Hashimoto G, Inoki I, Fujii Y, et al. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277:36288-36295.
43. Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog. 2006;2:e92.
44. Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline. Am J Trop Med Hyg. 2009;80:956-963.
45. Kon K, Fujii S, Kosaka H, Fujiwara T. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester retards vascular sprouting in angiogenesis. Microvasc Res. 2003;65:2-8.
46. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea. 1998;17:403-409.
47. Coxon A, Bolon B, Estrada J, et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum. 2002;46:2604-2612.
48. Stapleton WM, Chaurasia SS, Medeiros FW, et al. Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea. Exp Eye Res. 2008;86:753-757.
49. Yamada J, Dana MR, Sotozono C, Kinoshita S. Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res. 2003;76:161-167.
50. Nakao S, Hata Y, Miura M, et al. Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-κB-activated stromal cells in inflammatory angiogenesis. Am J Pathol. 2007;171:1058-1065.
51. Solomon A, Rosenblatt M, Li DQ, et al. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci. 2000;41:2544-2557.
52. Cazalis J, Bodet C, Gagnon G, Grenier D. Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models. J Periodontol. 2008;79:1762-1768.
53. D'Agostino P, La Rosa M, Barbera C, et al. Doxycycline reduces mortality to lethal endotoxemia by reducing nitric oxide synthesis via an interleukin-10-independent mechanism. J Infect Dis. 1998; 177:489-492.
54. D'Agostino P, Arcoleo F, Barbera C, et al. Tetracycline inhibits the nitric oxide synthase activity induced by endotoxin in cultured murine macrophages. Eur J Pharmacol. 1998;346:283-290.
55. Hoyt JC, Ballering J, Numanami H, et al. Doxycycline modulates nitric oxide production in murine lung epithelial cells. J Immunol. 2006;176:567-572.